Erasca, Inc. (Nasdaq: ERAS) released updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015 in patients with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE